Precision Oncology Approaches: Using Proteomics to Build Next-Gen Diagnostic Solutions

Life Sciences, Clinical Trials, Preclinical,
  • Thursday, April 20, 2023

Personalized oncology aims to match each patient to a specific therapy based on the molecular characteristics of their tumor. Currently, tumor DNA is sequenced, and genomics reports are given to physicians to help select targeted therapies for patients. While this genome-centric approach to precision oncology has extended the lives of subsets of patients, many patients do not respond to the selected therapy, and many whose tumors initially respond have a high chance of recurrence with resistant disease. New approaches are required to capture complex clinical phenotypes and better match patients to efficacious therapies.

Most molecularly targeted therapies (e.g., kinase inhibitors, immune checkpoint inhibitors) do not directly target the cancer genome but rather target proteins in cancer cells or the tumor microenvironment. Neither DNA nor RNA profiles are reliable indicators of protein expression or activity levels. Thus, directly quantifying the expression of target proteins and their networks throughout all phases of precision oncology, from drug development through to patient selection, is critically important.

This webinar will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology. The speaker will summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into: preclinical research; clinical trials and; clinical laboratories to support target discovery, pharmacodynamic and mechanism of action studies (e.g., PMID: 30385821, 34359745), correlative studies (e.g., PMID: 36259971) and the quantification of diagnostic proteins (e.g., PMID: 36388059). The establishment of proteomics represents an important component towards implementation of broader precision medicine efforts in oncology and beyond. (See also: PMID: 30487530 and PMID: 33798439.)

Register for this webinar to learn about the advantage of using proteomics to build next-gen diagnostic solutions for precision oncology.


Dr. Amanda Paulovich, Fred Hutchinson Cancer Center

Dr. Amanda Paulovich, MD, PhD, Professor and Aven Foundation Endowed Chair, Director, CLIA Targeted Proteomic Laboratory, Clinical Research Division, Fred Hutchinson Cancer Center

As an oncologist, Dr. Amanda Paulovich was struck by the paucity of quantitative assays for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized medicine.” Through these experiences, she became passionate about developing technologies and strategies for translation of NextGen diagnostics and therapeutics to enable precision medicine. Over the past 19 years, Dr. Paulovich’s interdisciplinary laboratory has focused on proteogenomic approaches to understanding cancer biology and laying the groundwork for the clinical translation of NextGen diagnostics incorporating targeted, multiple reaction monitoring (MRM) mass spectrometry.

Dr. Paulovich completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in oncology at Dana-Farber Cancer Institute. She completed her PhD training in genetics with Dr. Lee Hartwell at University of Washington and postdoctoral training in genomics at the Massachusetts Institute of Technology with Dr. Eric Lander.

Lab website:

Message Presenter

Who Should Attend?

Clinical and translational researchers from industry and academia interested in learning:

  • The state-of-the-art in mass spectrometry-based proteomics
  • How to incorporate proteomics into:
    • Preclinical translational research (e.g., target discovery, lead compound characterization)
    • Clinical trials (e.g., pharmacodynamic, mechanism of action, correlative studies)
    • Diagnostic testing

What You Will Learn

Attendees will gain insights into:

  • An understanding of state-of-the-art proteomic analyses
  • Application of proteogenomic approaches to identifying novel biomarkers
  • How to develop multiplex, targeted proteomic assays to support preclinical and clinical studies

Xtalks Partner


CellCarta is the leading provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials.

The company operates globally with 10 facilities located in Canada, USA, Belgium, Australia, and China.

For more information on how CellCarta can partner with you, please contact us:

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account